News

Nanobiotix inks US$56m deal
Enlarge image

BusinessFrance

Nanobiotix inks US$56m deal

07.08.2012 - In a deal worth $56m, Nanobiotix S.A. has entered into an exclusive partnership with PharmaEngine, Inc. for the rapid development of NBTXR3, a novel cancer nanotherapeutic.

With the partnership the Paris-based developer of the nanoparticle cancer radiotherapy booster NBTXR3 will speed up the global clinical development of its compound that is currently tested in a Phase I pilot study as treatment for soft tissue sarcoma. PharmaEngine will add its Asia-based complementary clinical development strengths and will conduct further clinical studies.

Under the terms of the agreement, Taiwanese PharmaEngine will receive exclusive rights to develop and commercialize NBTXR3 in the Asian-Pacific region, including Australia, China, India, Japan, Korea, Taiwan and other countries, while Nanobiotix retains exclusive rights for the rest of the world. Nanobiotix retains an option to re-acquire the rights for the entire Asian-Pacific territory except for China and Taiwan, according to pre-defined conditions in exchange for termination payments and agreed-upon royalties.

Nanobiotix will receive an initial upfront payment of US$ 1 million and commercialisation milestone payments of up to US$56m plus tiered, double-digit royalties on net product sales in the Asian-Pacific region. PharmaEngine will further fund the clinical development of NBTXR3 in three different indications with the goal to commence clinical studies in two indications within the next 18 months. The parties have agreed to share the data to enable an efficient and focused global development in multiple indications.

NBTXR3 is a nanoparticle formulation of hafnium oxide crystals for the local treatment of tumours to enhance the efficacy of radiotherapy. In a mouse model NBTRX tripled the generation of free radicals, thus NanoXray particles could change the clinical outcome. Taipei-based PharmaEngine adopts the business model of “no research, development only” and focuses on the development of new drugs for the treatment of cancer and Asian prevalent diseases.

http://www.european-biotechnology-news.com/news/news/2012-03/nanobiotix-out-licences-nano-cancer-drug.html

R&DEUBelgium

18.12.2014 IMI has launched a €115m call for proposals involving a project in collaboration with the Bill and Melinda Gates Foundation to improve vaccines against whopping cough in children.

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

RegulationUKFranceGermanySpain

01.12.2014 In spite of innovative new medicines on the market, the UK and Germany lag behind other countries and continue to use older medicines - especially in the treatment of cancer. French and Spanish patients, on the other hand, benefit much earlier from medical innovation.

Events

All Events

Current issue

All issues

Product of the week

Products